DNA Valuation

Ginkgo Bioworks Holdings Inc

Add to Watchlist

Advanced Chart

5.700

-0.260(-4.360%)

Overview
Forecast
Valuation

DNA Relative Valuation

DNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, DNA is overvalued; if below, it's undervalued.

Historical Valuation

Ginkgo Bioworks Holdings Inc(DNA) is now in theFairzone, suggesting that its currentforward PSratio of1.77is consideredFairlycompared with the five-year average of14.35.The fair price of Ginkgo Bioworks Holdings Inc(DNA)is between4.72to18.45according to relative valuation methord.

Relative Value

Fair Zone

4.72-18.45

Current Price：5.70

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

0.45

P/B

Median3y

1.96

Median5y

3.58

-124.18

FCF Yield

Median3y

-27.61

Median5y

-22.46

Competitors Valuation Multiple

The average P/S ratio for DNA's competitors is 1.51, providing a benchmark for relative valuation. Ginkgo Bioworks Holdings Inc Corp (DNA) exhibits a P/S ratio of 1.77, which is 16.74% above the industry average. Given its robust revenue growth of 26.16%, this premium appearssustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

DNA.N

Ginkgo Bioworks Holdings Inc